Skip to main content

Main menu

  • Home
  • Issues
    • Issue in progress
    • Issues by date
  • Sections
    • Editorial
    • Review
    • Research
    • Commentary
    • Psychopharmacology for the Clinician
    • Letters to the Editor
  • Topic Collections
  • Instructions for Authors
    • Overview for authors
    • Submission checklist
    • Editorial policies
    • Publication fees
    • Submit a manuscript
    • Dr. Francis Wayne Quan Memorial Prize
    • Open access
  • Alerts
    • Email alerts
    • RSS
  • About
    • General information
    • Staff
    • Editorial Board
    • Contact
  • CMAJ JOURNALS
    • CMAJ
    • CMAJ Open
    • CJS
    • JAMC

User menu

Search

  • Advanced search
JPN
  • CMAJ JOURNALS
    • CMAJ
    • CMAJ Open
    • CJS
    • JAMC
JPN

Advanced Search

  • Home
  • Issues
    • Issue in progress
    • Issues by date
  • Sections
    • Editorial
    • Review
    • Research
    • Commentary
    • Psychopharmacology for the Clinician
    • Letters to the Editor
  • Topic Collections
  • Instructions for Authors
    • Overview for authors
    • Submission checklist
    • Editorial policies
    • Publication fees
    • Submit a manuscript
    • Dr. Francis Wayne Quan Memorial Prize
    • Open access
  • Alerts
    • Email alerts
    • RSS
  • About
    • General information
    • Staff
    • Editorial Board
    • Contact
  • Subscribe to our alerts
  • RSS feeds
  • Follow JPN on Twitter
Psychopharmacology for the Clinician

Therapeutic abstention in the treatment of depression in first-episode psychosis

Priyadharshini Sabesan and Lena Palaniyappan
J Psychiatry Neurosci November 01, 2020 45 (6) 441-442; DOI: https://doi.org/10.1503/jpn.200059
Priyadharshini Sabesan
From the Department of Psychiatry, Schulich School of Medicine & Dentistry, University of Western Ontario London, Ont., Canada (Sabesan, Palaniyappan); and the Robarts Research Institute & Lawson Health Research Institute, London, Ont., Canada (Palaniyappan)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lena Palaniyappan
From the Department of Psychiatry, Schulich School of Medicine & Dentistry, University of Western Ontario London, Ont., Canada (Sabesan, Palaniyappan); and the Robarts Research Institute & Lawson Health Research Institute, London, Ont., Canada (Palaniyappan)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Responses
  • Metrics
  • PDF
Loading

A 26-year-old woman was referred to the emergency department for new-onset paranoia and auditory hallucinations.

Over the previous 2 months, she claimed that someone was replacing her furniture each night with replicas that changed in size. She also reported voices discussing how to change her clothes and asking her to urinate on her bed. She was waking up at 3 am, feeling sad and anxious. She also stopped going to work and using her bedroom.

On examination, she reported low mood, feelings of hopelessness, and guilt about not being able to work and being a burden for her husband. She appeared sad, avoided eye contact, and gave hesitant responses. She had limited insight regarding her delusions about the furniture. She admitted to thoughts of ending her life in response to the voices as well as the distress of losing work and having to stay at home where intruders were operating. No notable life events preceded the onset of psychosis, and her partner noted no change in her mood before this episode.

The patient was antipsychotic naive. Her father had a diagnosis of schizophrenia, with treatment details unknown. She had consulted her family doctor the previous year for low mood without psychotic symptoms, suicidal ideas, excess fatigue and crying spells that had lasted for 3 months. At the time, she reduced her working hours and received online counselling but refused antidepressants.

We administered the 6-item Positive and Negative Syndrome Scale (PANSS-6), on which she scored 23 out of 42 (the summed score of items P1–3 being 13), and the Calgary Depression Scale for Schizophrenia (CDSS), on which she scored 19 out of 27. She was started on aripiprazole 5 mg following admission. The dose was titrated to 10 mg after a week. She developed notable akathisia that resolved 2 days after the dose increases, with the use of clonazepam 1 mg on an as-required basis.

She expressed concerns about hospital workers intruding in her room and continued to experience auditory hallucinations instructing her and pre-empting her actions in the first 2 weeks of admission. These symptoms reduced in frequency and intensity over the subsequent 2 weeks. By week 4, she was keen to return home but continued to exhibit early morning awakening and feelings of guilt and episodic hopelessness. By week 5, she was no longer suicidal and scored 11 out of 42 on the PANSS-6, and 12 out of 27 on the CDSS. She was started on sertraline and discharged for outpatient follow-up. The dose was titrated to 100 mg by week 8, and by week 10, her CDSS score dropped to 6, and the PANSS-6 score dropped to 9.

Depressive symptoms are extremely common in first-episode psychosis (FEP), with 25%–50% of patients satisfying criteria for a major depressive episode (MDE), of whom nearly 50% show persistent depression at 1 year.1,2 Symptomatic relief from depression is a top priority for many patients.3 Evidence based on randomized controlled trials for addressing depression in FEP is sparse.4 Various national guidelines recommend active screening for depression in early psychosis but abstaining from intervention until positive symptoms resolve.4 Nevertheless, it is not clear how long intervention should be delayed when depression is prominent in FEP or how to respond if either psychosis or depression does not abate with first-line antipsychotics.

Therapeutic abstention is controversial and is based on limited case series data of non-FEP samples.4 In patients with FEP, 59% report persisting depression despite psychotic symptom resolution by the time of discharge.5 Only 15.2% of the variance in reduction of depression relates to the improvement in psychosis.6 The use of antidepressants appears to be well-tolerated and beneficial for pronounced depression in stable schizophrenia.7 Robust effects are noted with agents such as sertraline, and in samples with treatment resistance, although evidence in FEP is sparse7 and the choice of selective serotonin reuptake inhibitors is not always supported.8 More recently Goff and colleagues9 reported the lack of efficacy of citalopram for subthreshold depression (CDSS score < 7) in FEP over 1 year.

Therapeutic abstention is not advisable in the presence of mood-congruent psychosis.10 Earlier antidepressant use may also be required in patients with a documented history of MDE, as in our patient’s case. While early onset of action (by 2–4 weeks) for antipsychotics is well-established,11 in FEP cumulative improvement continues beyond a window of 4–24 weeks.12–15 An early evaluation of the relationship between CDSS and PANSS-6 scores may help in timely clinical decision making. With a more than 50% drop in PANSS-6 score, but a CDSS score still being clinically significant (> 7), antidepressant therapy was used in our patient’s case. Current guidelines recommend 6 months of use if antidepressants are needed in patients with schizophrenia.4 If both PANSS-6 and CDSS scores show no notable changes by weeks 4–6, a different second-generation antipsychotic can be considered. With depression being the most important risk factor for suicidality in FEP,16 earlier consideration of clozapine, an agent with anti-suicidal effects, may be warranted in the presence of depression.

Footnotes

  • The information in this column is not intended as a definitive treatment strategy but as a suggested approach for clinicians treating patients with similar histories. Individual cases may vary and should be evaluated carefully before treatment is provided. The patient described in this column is a composite with characteristics of several real patients.

  • Funding: L. Palaniyappan’s work is supported by the Canadian Institute of Health Research (Foundation Grant 375104), Bucke Family Fund and the Tanna Schulich Endowment Chair.

  • Competing interests: L. Palaniyappan reports personal fees from Janssen Canada, Otsuka Canada, SPMM Course Limited, UK, and the Canadian Psychiatric Association; book royalties from Oxford University Press; investigator-initiated educational grants from Sunovion, Janssen Canada, and Otsuka Canada; and travel support from Boehringer Ingelheim and Magstim Limited, outside the submitted work. He is a member of the JPN editorial board, but was not involved in the review or the decision to accept this manuscript for publication. P. Sabesan has received speaker fees from Lundbeck Canada.

References

  1. ↵
    1. Cotton SM,
    2. Lambert M,
    3. Schimmelmann BG,
    4. et al
    .Depressive symptoms in first episode schizophrenia spectrum disorder.Schizophr Res 2012;134:20–6.
    OpenUrlCrossRefPubMed
  2. ↵
    1. Sönmez N,
    2. Romm KL,
    3. Andreasssen OA,
    4. et al
    .Depressive symptoms in first episode psychosis: a one-year follow-up study.BMC Psychiatry 2013;13:106
    OpenUrlCrossRefPubMed
  3. ↵
    1. Moritz S,
    2. Berna F,
    3. Jaeger S,
    4. et al
    .The customer is always right? Subjective target symptoms and treatment preferences in patients with psychosis.Eur Arch Psychiatry Clin Neurosci 2017;267:335–9.
    OpenUrl
  4. ↵
    1. Dondé C,
    2. Vignaud P,
    3. Poulet E,
    4. et al
    .Management of depression in patients with schizophrenia spectrum disorders: a critical review of international guidelines.Acta Psychiatr Scand 2018;138:289–99.
    OpenUrl
  5. ↵
    1. Möller H-J
    .Occurrence and treatment of depressive comorbidity/cosyndromality in schizophrenic psychoses: conceptual and treatment issues.World J Biol Psychiatry 2005;6:247–63.
    OpenUrlCrossRefPubMed
  6. ↵
    1. Tapp A,
    2. Kilzieh N,
    3. Wood AE,
    4. et al
    .Depression in patients with schizophrenia during an acute psychotic episode.Compr Psychiatry 2001;42:314–8.
    OpenUrlCrossRefPubMed
  7. ↵
    1. Helfer B,
    2. Samara MT,
    3. Huhn M,
    4. et al
    .Efficacy and safety of antidepressants added to antipsychotics for schizophrenia: a systematic review and meta-analysis.Am J Psychiatry 2016;173:876–86.
    OpenUrl
  8. ↵
    1. Galling B,
    2. Vernon JA,
    3. Pagsberg AK,
    4. et al
    .Efficacy and safety of antidepressant augmentation of continued antipsychotic treatment in patients with schizophrenia.Acta Psychiatr Scand 2018;137:187–205.
    OpenUrl
  9. ↵
    1. Goff DC,
    2. Freudenreich O,
    3. Cather C,
    4. et al
    .Citalopram in first episode schizophrenia: the DECIFER trial.Schizophr Res 2019;208:331–7.
    OpenUrl
  10. ↵
    1. Farahani A,
    2. Correll CU
    .Are antipsychotics or antidepressants needed for psychotic depression? A systematic review and meta-analysis of trials comparing antidepressant or antipsychotic monotherapy with combination treatment.J Clin Psychiatry 2012;73:486–96.
    OpenUrlCrossRefPubMed
  11. ↵
    1. Emsley R,
    2. Rabinowitz J,
    3. Medori R
    .Time course for antipsychotic treatment response in first-episode schizophrenia.Am J Psychiatry 2006;163:743–5.
    OpenUrlCrossRefPubMed
  12. ↵
    1. Schennach-Wolff R,
    2. Jäger M,
    3. Mayr A,
    4. et al
    .Predictors of response and remission in the acute treatment of first-episode schizophrenia patients — Is it all about early response?.Eur Neuropsychopharmacol 2011;21:370–8.
    OpenUrlCrossRefPubMed
    1. Derks EM,
    2. Fleischhacker WW,
    3. Boter H,
    4. et al
    .Antipsychotic drug treatment in first-episode psychosis: Should patients be switched to a different antipsychotic drug after 2, 4, or 6 weeks of nonresponse?.J Clin Psychopharmacol 2010;30:176–80.
    OpenUrlCrossRefPubMed
    1. Emsley R,
    2. Oosthuizen PP,
    3. Kidd M,
    4. et al
    .Remission in first-episode psychosis: predictor variables and symptom improvement patterns.J Clin Psychiatry 2006;67:1707–12.
    OpenUrlCrossRefPubMed
  13. ↵
    1. Stentebjerg-Olesen M,
    2. Jeppesen P,
    3. Pagsberg AK,
    4. et al
    .Early nonresponse determined by the clinical global impressions scale predicts poorer outcomes in youth with schizophrenia spectrum disorders naturalistically treated with second-generation antipsychotics.J Child Adolesc Psychopharmacol 2013;23:665–75.
    OpenUrl
  14. ↵
    1. McGinty J,
    2. Sayeed Haque M,
    3. Upthegrove R
    .Depression during first episode psychosis and subsequent suicide risk: a systematic review and meta-analysis of longitudinal studies.Schizophr Res 2018;195:58–66.
    OpenUrl
PreviousNext
Back to top

In this issue

Journal of Psychiatry and Neuroscience: 45 (6)
J Psychiatry Neurosci
Vol. 45, Issue 6
1 Nov 2020
  • Table of Contents
  • Index by author

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on JPN.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Therapeutic abstention in the treatment of depression in first-episode psychosis
(Your Name) has sent you a message from JPN
(Your Name) thought you would like to see the JPN web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Therapeutic abstention in the treatment of depression in first-episode psychosis
Priyadharshini Sabesan, Lena Palaniyappan
J Psychiatry Neurosci Nov 2020, 45 (6) 441-442; DOI: 10.1503/jpn.200059

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
Therapeutic abstention in the treatment of depression in first-episode psychosis
Priyadharshini Sabesan, Lena Palaniyappan
J Psychiatry Neurosci Nov 2020, 45 (6) 441-442; DOI: 10.1503/jpn.200059
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

Similar Articles

Content

  • Current issue
  • Past issues
  • Collections
  • Alerts
  • RSS

Authors & Reviewers

  • Overview for Authors
  • Submit a manuscript
  • Manuscript Submission Checklist

About

  • General Information
  • Staff
  • Editorial Board
  • Contact Us
  • Advertising
  • Reprints
  • Copyright and Permissions
  • Accessibility
  • CMA Civility Standards
CMAJ Group

Copyright 2023, CMA Impact Inc. or its licensors. All rights reserved. ISSN 1180-4882.

All editorial matter in JPN represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.
To receive any of these resources in an accessible format, please contact us at CMAJ Group, 500-1410 Blair Towers Place, Ottawa ON, K1J 9B9; p: 1-888-855-2555; e: [email protected].
View CMA's Accessibility policy.

Powered by HighWire